SAREPTA THERAPEUTICS, INC. Shareholders' Equity
SAREPTA THERAPEUTICS, INC. (SRPT) had Shareholders' Equity of $1.53 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.53B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.51B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.14B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.32B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.53B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.51B 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $1.14B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $1.32B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.40B 10-Q · filed 2026-08-05 | $1.36B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.19B 10-Q · filed 2026-08-05 | $1.14B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.53B 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $1.22B 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.08B 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $961.19M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $859.34M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $764.36M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $741.41M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $712.75M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $384.95M 10-K · filed 2026-03-02 | |
| 2022-09-30 | $430.84M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $726.46M 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $856.89M 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $928.01M 10-K · filed 2025-02-28 | |
| 2021-09-30 | $469.53M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $485.11M 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $535.45M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $761.76M 10-K · filed 2024-02-28 | |
| 2020-09-30 | $892.05M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $1.04B 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $1.14B 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $818.19M 10-K · filed 2023-02-28 | |
| 2019-09-30 | $995.20M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.10B 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $1.35B 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $1.03B 10-K · filed 2022-03-01 | |
| 2018-09-30 | $639.85M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $699.05M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $776.76M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $789.22M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $697.16M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $377.77M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $429.14M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $336.69M 10-K · filed 2020-02-26 | |
| 2016-09-30 | $408.62M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $121.46M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $138.96M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $190.35M 10-K · filed 2019-02-28 | |
| 2015-09-30 | $123.24M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $165.38M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $200.76M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $247.65M 10-K · filed 2018-03-01 | |
| 2014-09-30 | $286.20M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $299.92M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $228.96M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $247.19M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $246.98M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $88.82M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $87.28M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $123.68M 10-K · filed 2014-03-03 | |
| 2012-09-30 | -$4.57M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $22.50M 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $14.02M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $31.02M 10-K · filed 2013-03-15 | |
| 2011-09-30 | $31.75M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $35.15M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | -$2.82M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |